Schiebinger R J, Parr H G, Cragoe E J
Wayne State University, Detroit, Michigan 48201.
Endocrinology. 1992 Feb;130(2):1017-23. doi: 10.1210/endo.130.2.1310273.
alpha 1-Adrenergic agonists increase atrial natriuretic peptide (ANP) secretion. The mechanism of alpha 1-adrenergic-stimulated secretion is not known. In this study we examine the calcium dependency of alpha 1-agonist-stimulated ANP secretion. Isolated superfused rat left atria paced at 2 Hz were used for study. Superfusion with 10 microM phenylephrine increased ANP secretion by 2-fold. Lowering the superfusate calcium concentration from 1.8 to 0.2 mM totally negated the secretory response to phenylephrine. To determine whether this reflected a reduction in calcium influx, reduced calcium release from the sarcoplasmic reticulum (SR), or both, atria were superfused with 1 microM ryanodine, an inhibitor of SR calcium release. Ryanodine had no effect on phenylephrine-stimulated ANP secretion. Atria were superfused with 10 microM nitrendipine to determine whether calcium influx through voltage-dependent calcium channels was a mechanism of calcium entry for stimulation. Nitrendipine inhibited phenylephrine-stimulated ANP secretion by 49% without interfering with alpha 1-adrenergic antagonist receptor binding. This finding was supported by the observation that phenylephrine-stimulated secretion was 52% lower in nonbeating atria. alpha 1-Adrenergic agonists have been reported to enhance Na-H antiporter activity. To determine whether the resulting rise in intracellular sodium may alter Na-Ca exchange to raise intracellular calcium levels, atria were superfused with the Na-H antiporter inhibitor, 5-(N,N-hexamethylene)amiloride. Superfusion with 25 microM 5-(N,N-hexamethylene)amiloride did not inhibit phenylephrine-stimulated ANP secretion. Lastly, the calcium dependency of the maintenance of an established response to phenylephrine was examined. Atria were superfused with phenylephrine in buffer containing 1.8 mM calcium for 45 min, followed by superfusion with phenylephrine in 0.2 mM calcium for 30 min. There was no fall in phenylephrine-stimulated secretion by atria superfused in 0.2 mM calcium. In contrast, addition of the alpha 1-adrenergic antagonist phentolamine induced an immediate fall in phenylephrine-stimulated ANP secretion. We conclude that 1) calcium influx is necessary to initiate alpha 1-agonist-stimulated ANP secretion; 2) calcium release from the SR does not play a role in alpha 1-agonist-stimulated secretion; 3) calcium entry through L-type calcium channels is responsible for half of the calcium influx; 4) enhanced Na-H antiporter activity does not play a role in alpha 1-agonist-stimulated secretion; and 5) maintenance of alpha 1-agonist-stimulated secretion is not dependent on calcium influx.
α1肾上腺素能激动剂可增加心房利钠肽(ANP)的分泌。α1肾上腺素能刺激分泌的机制尚不清楚。在本研究中,我们研究了α1激动剂刺激的ANP分泌对钙的依赖性。使用以2 Hz起搏的离体灌流大鼠左心房进行研究。用10 μM去氧肾上腺素灌流可使ANP分泌增加2倍。将灌流液钙浓度从1.8 mM降至0.2 mM完全消除了对去氧肾上腺素的分泌反应。为了确定这是否反映了钙内流的减少、肌浆网(SR)钙释放的减少或两者兼有,用1 μM雷诺丁(一种SR钙释放抑制剂)灌流心房。雷诺丁对去氧肾上腺素刺激的ANP分泌没有影响。用10 μM尼群地平灌流心房,以确定通过电压依赖性钙通道的钙内流是否是刺激时钙进入的一种机制。尼群地平抑制去氧肾上腺素刺激的ANP分泌49%,而不干扰α1肾上腺素能拮抗剂受体结合。这一发现得到了以下观察结果的支持:在非搏动心房中,去氧肾上腺素刺激的分泌降低了52%。据报道,α1肾上腺素能激动剂可增强Na-H反向转运体活性。为了确定由此导致的细胞内钠升高是否可能改变Na-Ca交换以提高细胞内钙水平,用Na-H反向转运体抑制剂5-(N,N-六亚甲基)阿米洛利灌流心房。用25 μM 5-(N,N-六亚甲基)阿米洛利灌流不抑制去氧肾上腺素刺激的ANP分泌。最后,研究了对去氧肾上腺素已建立反应的维持对钙的依赖性。在含有1.8 mM钙的缓冲液中用去氧肾上腺素灌流心房45分钟,然后在0.2 mM钙中用去氧肾上腺素灌流30分钟。在0.2 mM钙中灌流的心房中,去氧肾上腺素刺激的分泌没有下降。相反,加入α1肾上腺素能拮抗剂酚妥拉明可使去氧肾上腺素刺激的ANP分泌立即下降。我们得出结论:1)钙内流是启动α1激动剂刺激的ANP分泌所必需的;2)SR钙释放对α1激动剂刺激的分泌不起作用;3)通过L型钙通道的钙内流占钙内流的一半;4)增强的Na-H反向转运体活性对α1激动剂刺激的分泌不起作用;5)α1激动剂刺激的分泌的维持不依赖于钙内流。